BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 38004369)

  • 1. IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?
    Suzuki K; Yano S
    Life (Basel); 2023 Nov; 13(11):. PubMed ID: 38004369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma.
    Charliński G; Vesole DH; Jurczyszyn A
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials.
    Ye L; Zhou F; Cheng D; Xie M; Yan X; Xue Y; Yang Q; Jia R; Zhong L; Yang L; Zou L; Huang N
    Front Oncol; 2023; 13():1240318. PubMed ID: 38144527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma.
    Terpos E; Kanellias N; Christoulas D; Kastritis E; Dimopoulos MA
    Onco Targets Ther; 2013; 6():531-8. PubMed ID: 23690693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
    Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
    Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
    Bhutani M; Zhang Q; Friend R; Voorhees PM; Druhan LJ; Barlogie B; Sonneveld P; Morgan GJ; Symanowski JT; Avalos BR; Copelan EA; Usmani SZ
    Lancet Haematol; 2017 Sep; 4(9):e443-e451. PubMed ID: 28863804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical Approaches to the Management of Dual Refractory Multiple Myeloma.
    Lee HC; Mark TM; Shah JJ
    Curr Hematol Malig Rep; 2016 Apr; 11(2):148-55. PubMed ID: 26898556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulators in newly diagnosed multiple myeloma: current and future concepts.
    Delforge M; Vlayen S; Kint N
    Expert Rev Hematol; 2021 Apr; 14(4):365-376. PubMed ID: 33733978
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
    Raza S; Safyan RA; Lentzsch S
    Curr Cancer Drug Targets; 2017; 17(9):846-857. PubMed ID: 28201976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner.
    Dimopoulos K; Søgaard Helbo A; Fibiger Munch-Petersen H; Sjö L; Christensen J; Sommer Kristensen L; Asmar F; Hermansen NEU; O'Connel C; Gimsing P; Liang G; Grønbaek K
    Mol Oncol; 2018 Feb; 12(2):180-195. PubMed ID: 29130642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug Resistance.
    Davis LN; Walker ZJ; Reiman LT; Parzych SE; Stevens BM; Jordan CT; Forsberg PA; Sherbenou DW
    Clin Cancer Res; 2024 May; ():. PubMed ID: 38723281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma.
    Gooding S; Ansari-Pour N; Kazeroun M; Karagoz K; Polonskaia A; Salazar M; Fitzsimons E; Sirinukunwattana K; Chavda S; Ortiz Estevez M; Towfic F; Flynt E; Pierceall W; Royston D; Yong K; Ramasamy K; Vyas P; Thakurta A
    Blood; 2022 Oct; 140(16):1816-1821. PubMed ID: 35853156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.
    Tzogani K; Penninga E; Schougaard Christiansen ML; Hovgaard D; Sarac SB; Camarero Jimenez J; Garcia I; Lafuente M; Sancho-López A; Salmonson T; Gisselbrecht C; Pignatti F
    Oncologist; 2018 May; 23(5):594-602. PubMed ID: 29371479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
    Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
    Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulatory drugs in multiple myeloma.
    Andhavarapu S; Roy V
    Expert Rev Hematol; 2013 Feb; 6(1):69-82. PubMed ID: 23373782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Management of multiple myeloma in the relapsed/refractory patient].
    Tabayashi T
    Rinsho Ketsueki; 2019; 60(9):1257-1264. PubMed ID: 31597851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
    Gandhi UH; Cornell RF; Lakshman A; Gahvari ZJ; McGehee E; Jagosky MH; Gupta R; Varnado W; Fiala MA; Chhabra S; Malek E; Mansour J; Paul B; Barnstead A; Kodali S; Neppalli A; Liedtke M; Narayana S; Godby KN; Kang Y; Kansagra A; Umyarova E; Scott EC; Hari P; Vij R; Usmani SZ; Callander NS; Kumar SK; Costa LJ
    Leukemia; 2019 Sep; 33(9):2266-2275. PubMed ID: 30858549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma.
    Piggin A; Prince HM
    Expert Rev Hematol; 2021 May; 14(5):419-427. PubMed ID: 33945375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma.
    Hirano M; Imai Y; Kaito Y; Murayama T; Sato K; Ishida T; Yamamoto J; Ito T; Futami M; Ri M; Yasui H; Denda T; Tanaka Y; Ota Y; Nojima M; Kamikubo Y; Gotoh N; Iida S; Handa H; Tojo A
    J Exp Clin Cancer Res; 2021 Mar; 40(1):110. PubMed ID: 33757580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How I treat relapsed and/or refractory multiple myeloma.
    Lee HC; Cerchione C
    Hematol Rep; 2020 Sep; 12(Suppl 1):8955. PubMed ID: 33042504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.